Comparing the early immunological responses of liver transplant recipients treated under a bottom-up immunosuppressive regimen utilising either CsA or Everolimus
Final Report Abstract
P8 of KFO 243 was concerned with comparing three alternative immunosuppressive regimes which aimed to minimise calcineurin inhibitor (CNI) exposure in the early postoperative phase after liver transplantation in patients with a high pre-transplant MELD score. Specifically, the project objective was to determine whether bottom-up immunosuppression promotes beneficial “tolerogenic” responses by assessing a battery of immunological parameters in liver transplant recipients over time. Samples were to be obtained from patients enrolled in a Phase-II clinical trial of bottom-up immunosuppression in liver transplant recipients. Regrettably, patient recruitment to the BUILT01 study was significantly below expectation; accordingly, the goals of the first funding period have not been adequately fulfilled. Although the central objective of P8 was not achieved, the project was very successful in a number of important regards and the legacy of this project – an established platform for immune monitoring in solid organ transplant recipients – will benefit many other research projects at our institution, including projects proposed in the 2nd funding period of KFO 243.
Publications
-
(2015) First-in-human case study: multipotent adult progenitor cells for immunomodulation after liver transplantation. Stem Cells Transl Med. 4:899-904
Soeder Y, Loss M, Johnson CL, Hutchinson JA, Haarer J, Ahrens N, Offner R, Deans RJ, Van Bokkelen G, Geissler EK, Schlitt HJ, Dahlke MH
-
(2016) Early enrichment and restitution of the peripheral blood Treg pool is associated with rejection-free stable immunosuppression after liver transplantation. Transplantation. 100:e39-40
Haarer J, Riquelme P, Hoffmann P, Schnitzbauer A, Schlitt HJ, Sawitzki B, Geissler EK, Hutchinson JA
